Beam Therapeutics Inc.
BEAMNASDAQHealthcare● Active
$29.47
+$0.07(+0.24%)
Market Cap$3.0B
P/E Ratio—
52W High$36.44
52W Low$15.6
Beam Therapeutics Inc. (BEAM) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BEAM · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.14B | $0.06B | $0.38B | $0.06B | $0.05B |
| Cost of Revenue | $0.02B | $0.37B | $0.00B | $0.31B | $0.23B |
| Gross Profit | $0.12B | ($0.30B) | $0.38B | ($0.25B) | ($0.18B) |
| Gross Margin %(computed) | 84.05% | -478.67% | 100.00% | -411.48% | -347.75% |
| Operating Expenses | |||||
| R&D Expenses | $0.41B | $0.37B | $0.44B | $0.31B | $0.39B |
| G&A Expenses | $0.11B | $0.11B | $0.12B | $0.09B | $0.06B |
| Total Operating Expenses | $0.50B | $0.11B | $0.55B | $0.09B | $0.21B |
| Operating Income | ($0.38B) | ($0.42B) | ($0.18B) | ($0.34B) | ($0.39B) |
| Operating Margin %(computed) | -274.57% | -654.25% | -46.73% | -555.61% | -757.01% |
| Interest Income | $0.00B | $0.05B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.04B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.08B) | ($0.38B) | ($0.13B) | ($0.29B) | ($0.37B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.08B) | ($0.38B) | ($0.13B) | ($0.29B) | ($0.37B) |
| Net Margin %(computed) | -57.24% | -593.13% | -35.09% | -474.54% | -714.91% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.81 | $-4.58 | $-1.72 | $-4.13 | $-5.77 |
| Wtd Avg Shares | 0.10B | 0.08B | 0.08B | 0.07B | 0.06B |
| EBITDA | ($0.03B) | ($0.39B) | ($0.15B) | ($0.32B) | ($0.23B) |
| EBITDA Margin %(computed) | -21.41% | -619.73% | -38.91% | -532.39% | -443.76% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Beam Therapeutics Inc. data
About Beam Therapeutics Inc. (BEAM) Income Statement
Beam Therapeutics Inc. (BEAM) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, BEAM reported revenue of $0.14B, gross profit of $0.12B (gross margin 84.05%), and net income of ($0.08B) — a net profit margin of -57.24%.
Frequently asked questions
BEAM · 4 questionsBeam Therapeutics Inc. (BEAM) reported revenue of $0.14B for 2025, up 120.0% year-over-year.
BEAM revenueBEAM salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08